Pazopanib for the treatment of renal cell carcinoma

Future Oncology

Volumn 11, Issue 8, 2015, Pages 1169-1179

  Welsh, Sarah J ^a   Fife, Kate ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antiangiogenic; kidney; pazopanib; renal cancer; treatment; tyrosine kinase inhibitor

Indexed keywords

BIOLOGICAL MARKER; PAZOPANIB; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RESISTANCE; DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; LIVER TOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; DRUG-INDUCED LIVER INJURY; KIDNEY NEOPLASMS; PATHOLOGY; SECONDARY;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; DRUG-INDUCED LIVER INJURY; HUMANS; KIDNEY NEOPLASMS; PYRIMIDINES; SULFONAMIDES;

EID: 84926500486     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.274     Document Type: Review

References (39)

1. Ljungberg B, Campbell SC, Choi HY et al. The epidemiology of renal cell carcinoma. Eur. Urol. 60(4), 615-621 (2008).
2. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359-E386 (2014).
3. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 113, 78-83 (2008).
4. Welsh SJ, Janowitz T, Eisen T. The future for adjuvant therapy in renal cancer. Clin. Pract. 9(4), 451-462 (2012).
5. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353(9146), 14-17 (1999).
6. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6(Suppl. 1), S55-S57 (2000).
7. Gunturi A, McDermott DF. Potential of new therapies like anti-PD1 in kidney cancer. Curr. Treat. Options Oncol. 15(1), 137-146 (2014).
8. Welsh SJ, Janowitz T, Corrie P. Mechanism of action of approved anti-angiogenesis agents: overview for clinicians. Angiogenesis. Future Medicine, London, UK (2014).
9. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr. Oncol. Rep. 11(2), 94-101 (2009).
10. Eichmann A, Simons M. VEGF signalling inside vascular endothelial cells and beyond. Curr. Opin. Cell Biol. 24(2), 188-193 (2012).
11. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
12. Van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. Oncologist 17(8), 1081-1089 (2012).
13. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 15, 539-547 (2010).
14. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15(12), 4220-4227 (2009).
15. Hutson TE, Davis ID, Machiels JP et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 28(3), 475-480 (2010).
16. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
17. Sternberg CN, Hawkins RE, Wagstaff J et al. A randomised, double-blind Phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur. J. Cancer 49(6), 1287-1296 (2013).
18. Boleti E, Sarwar N, Jones R, Chowdhury S et al. The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer. J. Clin. Oncol. 30(Suppl. 5), Abstract 427 (2012).
19. Powles T, Blank C, Chowdhury S et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 60(3), 448-454 (2011).
20. Alvarez AL, Plimack ER, Dreicer R et al. A Phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN). J. Clin. Oncol. 32(5s Suppl.), Abstract 4522 (2014).
21. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369(8), 722-731 (2013).
22. Casper J, Schumann-Binarsch S, Köhne CH. Pazopanib versus sunitinib in renal cancer. N. Engl. J. Med. 369(20), 1969 (2013).
23. Wittes J. Pazopanib versus sunitinib in renal cancer. N. Engl. J. Med. 369(20), 1969 (2013).
24. Tanaka S, Kinjo Y, Kataoka Y, Yoshimura K, Termukai S. Statistical issues and recommendations for noninferiority trials in oncology: a systematic review. Clin. Cancer Res. 18, 1837-1184 (2012).
25. Escudier B, Porta C, Bono P et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J. Clin. Oncol. 32(14), 1412-1418 (2014).
26. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
27. Motzer R, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008).
28. Reeves J, Spigel D, Daniel D et al. Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: a Sarah Cannon Research Institute Phase II trial. J. Clin. Oncol. 29(Suppl.), Abstract 4659 (2011).
29. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir N. Metastatic renal cell carcinoma treated with pazopanib after progression on other targeted agents: a single-institution experience. J. Clin. Oncol. 29(Suppl. 7), Abstract 351 (2011).
30. Dranitsaris G, Schmitz S, Broom RJ. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. J. Cancer Res. Clin. Oncol. 139(11), 1917-1926 (2013).
31. Maroto P, Rini B. Molecular biomarkers in advanced renal cell carcinoma. Clin. Cancer Res. 20(8), 2060-2071 (2014).
32. Bex A, Fournier L, Lassau N et al. Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. Eur. Urol. 65(4), 766-777 (2014).
33. Bettegowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6(224), 224ra24 (2014).
34. Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann. Oncol. 25(12), 2304-2313 (2014).
35. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17(3), 471-494 (2014).
36. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33(4), 207-214 (2012).
37. Tibes R, Falchook GS, Von Hoff DD et al. Results from a Phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. J. Clin. Oncol. 28(15s Suppl.), Abstract 3076 (2010).
38. Figlin RA, Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int. J. Cancer 133(4), 788-796 (2013).
39. de Jonge MJ, Hamberg P, Verweij J et al. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest. New Drugs 31(3), 751-759 (2013).